1. Home
  2. VALN vs DNA Comparison

VALN vs DNA Comparison

Compare VALN & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VALN
  • DNA
  • Stock Information
  • Founded
  • VALN 2012
  • DNA 2008
  • Country
  • VALN France
  • DNA United States
  • Employees
  • VALN N/A
  • DNA N/A
  • Industry
  • VALN Biotechnology: Biological Products (No Diagnostic Substances)
  • DNA Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • VALN Health Care
  • DNA Health Care
  • Exchange
  • VALN Nasdaq
  • DNA Nasdaq
  • Market Cap
  • VALN 510.7M
  • DNA 478.8M
  • IPO Year
  • VALN 2021
  • DNA N/A
  • Fundamental
  • Price
  • VALN $6.79
  • DNA $7.85
  • Analyst Decision
  • VALN Strong Buy
  • DNA Sell
  • Analyst Count
  • VALN 2
  • DNA 5
  • Target Price
  • VALN $16.00
  • DNA $17.25
  • AVG Volume (30 Days)
  • VALN 142.9K
  • DNA 1.6M
  • Earning Date
  • VALN 05-06-2025
  • DNA 05-08-2025
  • Dividend Yield
  • VALN N/A
  • DNA N/A
  • EPS Growth
  • VALN N/A
  • DNA N/A
  • EPS
  • VALN N/A
  • DNA N/A
  • Revenue
  • VALN $175,564,758.00
  • DNA $227,043,000.00
  • Revenue This Year
  • VALN $19.17
  • DNA N/A
  • Revenue Next Year
  • VALN $26.31
  • DNA $16.85
  • P/E Ratio
  • VALN N/A
  • DNA N/A
  • Revenue Growth
  • VALN 10.32
  • DNA N/A
  • 52 Week Low
  • VALN $3.62
  • DNA $5.00
  • 52 Week High
  • VALN $9.50
  • DNA $45.20
  • Technical
  • Relative Strength Index (RSI)
  • VALN 50.63
  • DNA 53.59
  • Support Level
  • VALN $6.54
  • DNA $7.93
  • Resistance Level
  • VALN $7.30
  • DNA $8.58
  • Average True Range (ATR)
  • VALN 0.48
  • DNA 0.81
  • MACD
  • VALN 0.01
  • DNA 0.36
  • Stochastic Oscillator
  • VALN 56.79
  • DNA 77.24

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

About DNA Ginkgo Bioworks Holdings Inc.

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

Share on Social Networks: